Company Filing History:
Years Active: 2005
Title: Johanna Aaltonen: Innovator in Genetic Research
Introduction
Johanna Aaltonen is a prominent inventor based in Helsinki, Finland. She has made significant contributions to the field of genetic research, particularly in understanding autoimmune diseases. Her work has led to advancements in genetic diagnosis and the molecular understanding of specific conditions.
Latest Patents
Johanna Aaltonen holds a patent for a nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED). This patent is crucial as APECED is the only known systemic autoimmune disease with a monogenic background. The research led to the isolation of a novel polynucleotide located on chromosome 21q22.3, identifying five different mutations in APECED patients from various populations. The polypeptide encoded by this polynucleotide is named APGD1, which consists of 545 amino acid residues and features two Cys(4)-His-Cys(3) double-paired finger motifs similar to PHD finger domains. This identification facilitates direct genetic diagnosis of APECED and provides tools for understanding the disease's molecular pathogenesis.
Career Highlights
Johanna Aaltonen is affiliated with the National Public Health Institute, where she conducts her research. Her work has been instrumental in advancing the understanding of genetic factors in autoimmune diseases. She has dedicated her career to unraveling the complexities of genetic mutations and their implications for health.
Collaborations
Johanna has collaborated with notable colleagues, including Leena Peltonen and Petra Björses. These collaborations have enriched her research and contributed to the broader scientific community's understanding of genetic disorders.
Conclusion
Johanna Aaltonen's innovative work in genetic research has paved the way for advancements in the diagnosis and understanding of autoimmune diseases. Her contributions are vital for future research and therapeutic developments in this field.